Prognostic value of Th17 cells in acute leukemia

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Abousamra, Nashwa Khairat ^a   Salah El Din, Manal ^a   Helal, Randah ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Acute leukemia; IL 17; IL 21; Th17 cells

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MIDDLE AGED; NEUTROPHIL COUNT; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; YOUNG ADULT; ACUTE DISEASE; BLOOD; LEUKEMIA; MONONUCLEAR CELL; NORMAL HUMAN; PATHOLOGY; PROGNOSIS; REMISSION; TH17 CELL;

INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE;

ACUTE DISEASE; ADULT; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TH17 CELLS; YOUNG ADULT;

EID: 84891866507     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0732-3     Document Type: Article

References (31)

1. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903-7. (Pubitemid 350231320)
2. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-15. (Pubitemid 351860863)
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P, Trajanoski Z, Fridman W, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-4. (Pubitemid 44498003)
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-13. (Pubitemid 36077915)
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538-43. (Pubitemid 43011261)
6. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9. (Pubitemid 39273735)
7. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;6(114):1141-9.
8. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8:337-48. (Pubitemid 351595217)
9. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007;19:652-7. (Pubitemid 350236805)
10. Ersvaer E, Melve GK, Bruserud O. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunol Immunother. 2011;60:1669-81.
11. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730-3. (Pubitemid 46847396)
12. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183:4169-75.
13. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357-9.
14. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484-7. (Pubitemid 47123515)
15. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480-3. (Pubitemid 47123514)
16. Li P, Ji M, Park J, Bunting KD, Ji C, Tse W. Th17 related cytokines in acute myeloid leukemia. Front Biosci. 2012;17:2284-94.
17. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 2009;158:199-204.
18. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010;9:11-38.
19. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumors of haematopoietic and lymphoid tissue. 4th ed. Lyon: IARC; 2008.
20. Luo X, Tan H, Zhou Y, Xiao T, Wang C, Li Y. Notch1 signaling is involved in regulating Foxp3 expression in T-ALL. Cancer Cell Int. 2013;13:34.
21. Ji Y, Zhang W. Th17 cells: positive or negative role in tumor. Cancer Immunol Immunother. 2010;59:979-87.
22. Su MF, Wang CF, Zhao YM, Wu JX, Zhang Y. Expression and clinical significance of IL-17 and IL-21 in patients with acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:1143-6.
23. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC. Restifo NP Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362-73.
24. Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P, et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol. 2010;185:4063-71.
25. Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep. 2009;22:337-43.
26. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10:248-56.
27. Yan XJ, Li W, Yancopoulos S, Dozmorov I, Centola M, Allen SL, Rai KR, Chiorazzi N, Sherry B. Identification of distinct cytokine and chemokine clusters that correlate with outcome in B-cell chronic lymphocytic leukemia: implications for disease pathogenesis. Blood. 2010;116:1368.
28. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012;97:599-607.
29. He S, Fei M, Wu Y, Zheng D, Wan D, Wang L, Li D. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011;12:7424-37.
30. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008;1:4723-30.
31. Brenne AT, Baade Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002;99:3756-62. (Pubitemid 34534548)